• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    InspireMD Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    6/3/26 4:05:25 PM ET
    $NSPR
    Medical/Dental Instruments
    Health Care
    Get the next $NSPR alert in real time by email
    false --12-31 0001433607 0001433607 2026-06-03 2026-06-03 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    FORM 8-K

     

     

     

    CURRENT REPORT

     

    Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): June 3, 2026

     

     

     

    InspireMD, Inc.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   001-35731   26-2123838
    (State or other jurisdiction   (Commission   (IRS Employer
    of incorporation)   File Number)   Identification No.)

     

    6303 Waterford District Drive, Suite 215    
    Miami, Florida 33126   6744832
    (Address of principal executive offices)   (Zip Code)

     

    Registrant’s telephone number, including area code: (888) 776-6804

     

     

    (Former name or former address, if changed since last report.)

     

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common Stock, $0.0001 par value per share   NSPR   The Nasdaq Capital Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     
     

     

    Item 5.03 Amendment to Articles of Incorporation or Bylaws; Change in Fiscal Year.

     

    As further described in Item 5.07 below, on June 3, 2026, InspireMD, Inc. (the “Company”) held its 2026 annual meeting of stockholders (the “Annual Meeting”). At the Annual Meeting, the stockholders approved, among other things, an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the authorized number of shares of the Company’s common stock from 150,000,000 shares to 250,000,000 shares (the “Amendment”). The Amendment became effective upon the Company’s filing of a Certificate of Amendment to the Company’s Amended and Restated Certificate of Incorporation with the Secretary of State of Delaware on June 3, 2026 (the “Certificate of Amendment”). The foregoing description of the Amendment is qualified in its entirety by reference to the full text of the Certificate of Amendment, a copy of which is attached as Exhibit 3.1 hereto and is incorporated by reference herein.

     

    Item 5.07. Submission of Matters to a Vote of Security Holders.

     

    On June 3, 2026, the Company held its Annual Meeting. As of April 10, 2026, the record date for the Annual Meeting, there were 46,892,979 shares of common stock issued and outstanding and entitled to vote on the proposals presented at the Annual Meeting, of which 34,631,348, or 73.85%, were present in person or represented by proxy, which constituted a quorum. The holders of shares of the Company common stock are entitled to one vote for each share held. Set forth below are the final voting results for each of the proposals submitted to a vote of the Company’s stockholders at the Annual Meeting.

     

    Proposal No. 1 - Election of Directors.

     

    The stockholders re-elected Marvin Slosman, Raymond Cohen and Dan Dearen to serve on the board of directors of the Company, as Class 3 directors, for a term of three years or until their respective successor is elected and qualified. The votes were as follows:

     

    Director Name   For   Withheld   Broker Non-Votes
    Marvin Slosman   25,086,284   1,728,950   7,816,114
    Raymond Cohen   22,733,263   4,081,971   7,816,114
    Dan Dearen   22,750,906   4,064,328   7,816,114

     

    Proposal No. 2 – Increase in Authorized Shares.

     

    The stockholders approved an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the authorized number of shares of the Company’s common stock from 150,000,000 shares to 250,000,000 shares. The votes were as follows:

     

    For   Against   Withheld   Broker Non-Votes
    31,577,297   3,009,107   44,944   0

     

    Proposal No. 3 - Ratification of Auditors.

     

    The stockholders ratified the appointment of Kesselman & Kesselman, a member of PricewaterhouseCoopers International Limited, as the Company’s independent registered public accounting firm for the 2026 fiscal year. The votes were as follows:

     

    For   Against   Abstain
    34,355,150   244,248   31,950

     

    Based on the foregoing votes, Proposals 1 through 3 were approved. As there were sufficient votes to approve the proposals, the proposal to approve an adjournment of the Annual Meeting to a later date or dates, if necessary, to permit further solicitation and vote of proxies in the event there are not sufficient votes to establish a quorum or in favor of proposals 1 through 3 was not presented to the Company’s stockholders.

     

    Item 9.01 Financial Statements and Exhibits.

     

    (d) Exhibits.

     

    Exhibit Number   Description
    3.1   Certificate of Amendment to Amended and Restated Certificate of Incorporation of InspireMD, Inc.
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

     
     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      INSPIREMD, INC.
         
    Date: June 3, 2026 By: /s/ Marvin Slosman
      Name: Marvin Slosman
      Title: Chief Executive Officer

     

     

    Get the next $NSPR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NSPR

    DatePrice TargetRatingAnalyst
    2/2/2026$6.00Buy
    Maxim Group
    More analyst ratings

    $NSPR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Stuka Paul bought $17,500 worth of shares (20,000 units at $0.88), increasing direct ownership by 3% to 667,871 units (SEC Form 4)

    4 - InspireMD, Inc. (0001433607) (Issuer)

    5/29/26 4:05:10 PM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    Chief Commercial Officer Gleason Shane Thomas sold $189,594 worth of shares (85,295 units at $2.22), decreasing direct ownership by 7% to 1,053,882 units (SEC Form 4) (for tax liability)

    4 - InspireMD, Inc. (0001433607) (Issuer)

    5/21/26 5:16:56 PM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    Director Stuka Paul bought $17,325 worth of shares (15,000 units at $1.16), increasing direct ownership by 2% to 647,871 units (SEC Form 4)

    4 - InspireMD, Inc. (0001433607) (Issuer)

    5/15/26 4:05:07 PM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    $NSPR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Stuka Paul bought $17,500 worth of shares (20,000 units at $0.88), increasing direct ownership by 3% to 667,871 units (SEC Form 4)

    4 - InspireMD, Inc. (0001433607) (Issuer)

    5/29/26 4:05:10 PM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    Director Stuka Paul bought $17,325 worth of shares (15,000 units at $1.16), increasing direct ownership by 2% to 647,871 units (SEC Form 4)

    4 - InspireMD, Inc. (0001433607) (Issuer)

    5/15/26 4:05:07 PM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    CEO and President Slosman Marvin bought $25,200 worth of shares (21,000 units at $1.20), increasing direct ownership by 0.59% to 3,556,658 units (SEC Form 4)

    4 - InspireMD, Inc. (0001433607) (Issuer)

    5/13/26 5:00:17 PM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    $NSPR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    InspireMD Announces First Patient Enrolled in the CGUARDIANS III Pivotal Study of the SwitchGuard Neuro Protection System for Use in TCAR Procedures

    MIAMI, June 08, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR) ("InspireMD" or the "Company"), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced that the first patient has been enrolled in the CGUARDIANS III pivotal study of its SwitchGuard neuro protection system ("NPS"), for use with its CGuard Prime 80 cm stent platform, in transcarotid artery revascularization ("TCAR") procedures. The patient was enrolled by Dr. Patrick Muck at Good Samaritan Hospital, part of the TriHealth System in Cincinnati, Ohio. Dr. Muck and Dr. Patrick Geraghty, professor of surgery and radiology, section of vascular surgery at Washington University School

    6/8/26 8:00:00 AM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    InspireMD to Participate in Upcoming Bank of America Securities 2026 Global Healthcare Conference

    MIAMI, May 06, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR) ("InspireMD" or the "Company"), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced plans to present at the upcoming Bank of America Securities 2026 Global Healthcare Conference on Wednesday, May 13th at 4:20 pm Pacific Time (PT). A live audio webcast and an archive of the recording will be available through the Investors page of InspireMD's corporate website at https://investors.inspiremd.com. About InspireMD, Inc.InspireMD seeks to utilize its proprietary MicroNet™ mesh technology to make its products the industry standard for carotid stenting by providing outstanding acu

    5/6/26 4:05:00 PM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    InspireMD Announces FDA Approval of Investigational Device Exemption Application for CGUARDIANS III Pivotal Study of the SwitchGuard Neuro Protection System

    MIAMI, May 01, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR) ("InspireMD" or the "Company"), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced that the U.S. Food and Drug Administration ("FDA") has approved the company's Investigational Device Exemption ("IDE") Application to initiate the CGUARDIANS III pivotal study of its SwitchGuard neuro protection system ("NPS"), including next generation enhancements from our prior IDE approval for use with its CGuard Prime 80 cm stent platform, in transcarotid artery revascularization ("TCAR") procedures. Patrick Geraghty, M.D., professor of surgery and radiology, section of vascular surgery

    5/1/26 4:05:00 PM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    $NSPR
    SEC Filings

    View All

    InspireMD Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - InspireMD, Inc. (0001433607) (Filer)

    6/3/26 4:05:25 PM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    InspireMD Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - InspireMD, Inc. (0001433607) (Filer)

    5/22/26 4:05:34 PM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by InspireMD Inc.

    10-Q - InspireMD, Inc. (0001433607) (Filer)

    5/7/26 8:53:25 AM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    $NSPR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Maxim Group initiated coverage on InspireMD with a new price target

    Maxim Group initiated coverage of InspireMD with a rating of Buy and set a new price target of $6.00

    2/2/26 7:53:56 AM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    $NSPR
    Leadership Updates

    Live Leadership Updates

    View All

    InspireMD Names Peter A. Soukas, M.D., as Chief Medical Officer

    MIAMI, Nov. 03, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR) ("InspireMD" or the "Company"), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced the appointment of Peter A. Soukas, M.D., as Chief Medical Officer to advance its mission to deliver best-in-class tools for carotid intervention. "We are thrilled to have Dr. Soukas join InspireMD to help lead our clinical and medical organization with strategy and oversight at this pivotal time for the Company," said Marvin Slosman, Chief Executive Officer of InspireMD. "His expertise and clinical practice focus in carotid intervention and peripheral vascular disease offer valuable insight

    11/3/25 7:30:00 AM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    InspireMD Announces the Appointment of Dan Dearen to its Board of Directors

    MIAMI, Sept. 17, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR) ("InspireMD" or the "Company"), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced the appointment of Dan Dearen to its Board of Directors. Mr. Dearen brings nearly 40 years of leadership experience in the medical device and life sciences sectors, with a proven track record of guiding MedTech companies through critical financial milestones and delivering shareholder value through execution. "We are pleased to welcome Dan to InspireMD's Board of Directors," said Marvin Slosman, Chief Executive Officer of InspireMD. "He brings extensive experience, financial expertise, and

    9/17/25 8:00:00 AM ET
    $BBNX
    $NSPR
    Medical/Dental Instruments
    Health Care

    InspireMD Announces the Appointment of Raymond W. Cohen to its Board of Directors

    MIAMI, July 31, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR) ("InspireMD" or the "Company"), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced the appointment of Raymond W. Cohen to its Board of Directors. Mr. Cohen has over 40 years of leadership experience in medical technology with a successful track record of scaling commercial operations and creating shareholder value through market leadership and successful exit transactions. "We are thrilled to welcome Ray to InspireMD's Board of Directors," said Marvin Slosman, Chief Executive Officer of InspireMD. "We expect to benefit greatly from his vast insights and experience. His

    7/31/25 8:31:00 AM ET
    $KMTS
    $NSPR
    Medical/Dental Instruments
    Health Care

    $NSPR
    Financials

    Live finance-specific insights

    View All

    InspireMD to Announce First Quarter 2026 Financial Results

    MIAMI, April 27, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced that it will release its first quarter financial results on Monday, May 4, 2026. In conjunction with the release, InspireMD will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss its financial results and recent highlights. Parties interested in participating by phone should register using this online form. After registering for the webcast, dial-in details will be provided in an auto-generated e-mail containing a link to the conference phone number along with a personal pin. A live audio webcast an

    4/27/26 4:05:00 PM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    InspireMD Reports Fourth Quarter and Full Year 2025 Financial Results

    MIAMI, March 18, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR) ("InspireMD" or the "Company"), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced financial and operating results for the fourth quarter and year ended December 31, 2025. Recent Business Highlights: Generated revenue of $3.1 million in the fourth quarter of 2025, up 62% year-over-year.Sustained strong commercial traction in the U.S. with the launch of CGuard Prime and continued growth in international demand for CGuard.Supported over 500 cumulative carotid procedures utilizing CGuard Prime across leading hospitals and integrated delivery networks since launch.Co

    3/18/26 7:00:00 AM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    InspireMD to Announce Fourth Quarter and Full Year 2025 Financial Results

    MIAMI, March 09, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced that it will release its fourth quarter and full year 2025 financial results on Wednesday, March 18, 2026. In conjunction with the release, InspireMD will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss its financial results and recent highlights. A live audio webcast and an archive of the recording will be available through the Investors page of InspireMD's corporate website at https://investors.inspiremd.com. Interested participants are encouraged to register more than 15 minutes before the star

    3/9/26 9:00:00 AM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    $NSPR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by InspireMD Inc.

    SC 13G - InspireMD, Inc. (0001433607) (Subject)

    12/4/24 4:31:06 PM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by InspireMD Inc.

    SC 13G/A - InspireMD, Inc. (0001433607) (Subject)

    11/14/24 6:35:20 PM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by InspireMD Inc.

    SC 13G/A - InspireMD, Inc. (0001433607) (Subject)

    10/28/24 4:02:11 PM ET
    $NSPR
    Medical/Dental Instruments
    Health Care